research communications
1.12 Å resolution
of the of the plasmid-mediated colistin resistance determinant MCR-2aSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, England, and bDepartment of Medical Microbiology and Infectious Disease, Cardiff Institute of Infection and Immunity, UHW Main Building, Heath Park Hospital, Cardiff CF14 4XN, Wales
*Correspondence e-mail: philip.hinchliffe@bristol.ac.uk
MCR-2 confers resistance to colistin, a `last-line' antibiotic against extensively resistant Gram-negative pathogens. It is a plasmid-encoded phosphoethanolamine transferase that is closely related to MCR-1. To understand the diversity in the MCR family, the 1.12 Å resolution
of the of MCR-2 was determined. Variable amino acids are located distant from both the di-zinc active site and the membrane-proximal face. The exceptionally high resolution will provide an accurate starting model for further mechanistic studies.Keywords: MCR-1; antibiotic resistance; colistin; MCR-2; polymixin.
PDB reference: MCR-2 5mx9
1. Introduction
The polymyxin colistin is a key `last-resort' antibiotic used to treat infections by multidrug-resistant Gram-negative pathogens (Biswas et al., 2012; Karaiskos et al., 2017). The positively charged cyclic peptide of colistin binds to the negatively charged lipid A headgroup, with the hydrophobic tail inserting into, and disrupting, the outer membrane (Clausell et al., 2007; Wiese et al., 2003). A key colistin resistance mechanism is the production of MCR-1 (Liu et al., 2016), a plasmid-encoded phosphoethanolamine transferase that has disseminated worldwide. It is found in clinical strains of Escherichia coli and Klebsiella pneumoniae (Liu et al., 2016), and in bacteria producing other resistance determinants, such as carbapenemases (Mediavilla et al., 2016; Haenni et al., 2016), which can result in essentially untreatable bacterial infections.
MCR-1 catalyses the transfer of positively charged phosphoethanolamine onto lipid A, which is subsequently incorporated into the outer membrane, reducing the net negative charge and preventing colistin binding (Hinchliffe et al., 2017; Liu et al., 2016). It is an integral, metal-dependent inner-membrane protein, with a large periplasmic domain containing the catalytic centre and the conserved Thr285 that is likely to act as the acceptor for the phosphoethanolamine group during the transfer reaction (Hinchliffe et al., 2017). We recently described two crystal structures of the MCR-1 (MCR-1CD), revealing the presence of one (PDB entry 5lrn; MCR-15LRN) or two (PDB entry 5lrm; MCR-15LRM) zinc ions in the active site (Hinchliffe et al., 2017), with the proposed catalytic Thr285 phosphorylated or not phosphorylated, respectively. Additional MCR-1CD structures have been reported: two with phosphorylated Thr285 and crystallized from conditions with a nonphysiologically high zinc content [PDB entries 5gov (MCR-15GOV; Hu et al., 2016) and 5k4p (MCR-15K4P; Stojanoski et al., 2016)], and consequently containing additional zinc ions, and one with two active-site zinc ions and both phosphorylated and nonphosphorylated Thr285 (PDB entry 5grr; MCR-15GRR; Ma et al., 2016). More recently, the full-length, detergent-solubilized of an MCR homologue (EptA; 36% sequence identity to MCR-2) was solved (Anandan et al., 2017) with a single zinc ion, a nonphosphorylated Thr285 and a bound molecule of dodecyl maltoside (DDM) in the active site. This full-length structure confirmed the prediction (Hinchliffe et al., 2017) that the active site is proximal to the membrane.
Two genes closely related to mcr-1 have also been identified. Firstly, mcr1.2, containing a Gln3Leu substitution, was found in a K. pneumoniae strain (Di Pilato et al., 2016). Secondly, mcr-2 was detected in colistin-resistant E. coli isolated from porcine and bovine samples, with a higher prevalence than mcr-1 in the porcine samples (Xavier et al., 2016). mcr-2 is harboured on a plasmid (IncX4) with a high transfer frequency that appears to lack a fitness cost to the host and can harbour MCR-1 (Fernandes et al., 2016; Li, Yang et al., 2016) alongside extended-spectrum β-lactamases such as TEM and CTX-M (Li, Xie et al., 2016; Falgenhauer et al., 2016; Lo et al., 2014). MCR-2 (538 residues) is 81% identical to MCR-1 (Fig. 1), with 101 amino-acid substitutions (61 in the transmembrane domain and 40 in the catalytic domain) and three deletions (Met1 and Leu68 in the transmembrane domain and Gln501 in the MCR-1 numbering is used throughout). Residues previously identified as essential (Glu246, His395 and the site Thr285) or important (Lys333, Glu468 and His478) for MCR-1 activity (Hinchliffe et al., 2017) are strictly conserved in MCR-2 (red or yellow triangles, respectively, in Fig. 1), indicating a likely identical catalytic mechanism. To understand MCR diversity, we have solved the of the MCR-2 (residues 217–538; MCR-2CD), which is 87% identical to MCR-1CD.
2. Materials and methods
2.1. Macromolecule production
To facilitate structural studies, we removed the transmembrane domain and synthesized mcr-2 codons 217–538 (Eurofins), and subcloned them into pOPIN-F (Berrow et al., 2007) using the primers in Table 1, resulting in plasmid pOPINF-MCR2217–538 encoding N-terminally His6-tagged protein (Table 1). The protein was purified as for MCR-1CD (Hinchliffe et al., 2017). Briefly, E. coli SoluBL21 cells bearing pOPINF-MCR2217–538 were induced at 18°C with IPTG overnight and the protein was purified using Ni–NTA The buffers contained 100 µM ZnCl2 throughout, and the tag was removed by 3C protease cleavage and captured on Ni–NTA resin. Protein was loaded onto a Superdex 75 size-exclusion column equilibrated in 50 mM HEPES pH 7.5, 150 mM NaCl, 100 µM ZnCl2. As for MCR-1CD (Hinchliffe et al., 2017; Ma et al., 2016), MCR-2CD eluted from the Superdex 75 column as a monomer. Peak fractions were concentrated to 15 mg ml−1 by centrifugation.
|
2.2. Crystallization
Crystallization screens were conducted in MRC 2-drop 96-well sitting-drop plates using commercially available sparse-matrix screens (JCSG-plus, ProPlex, Structure Screen 1 + 2, Morpheus and PACT Premier from Molecular Dimensions). Crystals were obtained by mixing 0.4 µl protein solution (15 mg ml−1) with 0.2 µl reservoir solution (0.1 M KSCN, 30% PEG 2000 MME) and equilibrating against 50 µl reservoir solution (Table 2), were harvested in reservoir plus 25% glycerol and were flash-cooled in liquid nitrogen.
|
2.3. Data collection and processing
X-ray data (Table 3) were collected at 100 K on beamline I04 at Diamond Light Source (DLS), UK, integrated in DIALS (Waterman et al., 2016) and scaled using AIMLESS (Evans & Murshudov, 2013) in the CCP4 suite (Winn et al., 2011).
|
2.4. Structure solution and refinement
Crystallographic phases were solved using Phaser (McCoy et al., 2007) with MCR-1CD (PDB entry 5lrn) as the starting model. Variable amino acids were altered to the MCR-2 sequence and the model was completed by iterative rounds of manual model building and in Coot (Emsley et al., 2010) and PHENIX (Adams et al., 2010). B factors were refined anisotropically, except for H atoms and water molecules, which were refined isotropically. Structure validation was assisted by MolProbity (Chen et al., 2010) and PHENIX. Details of the are shown in Table 4. Atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB entry 5mx9).
|
3. Results and discussion
The overall MCR-2CD fold contains three disulfide bonds and is essentially identical to that of MCR-15LRN (root-mean-square deviation of 0.54 Å over 314 Cα atoms calculated using PDBeFold; Krissinel & Henrick, 2004; Fig. 2a). A single residue (Ser330) is a Ramachandran plot outlier, with φ and ψ values of −165.9 and −82.4°, respectively. This residue is sterically strained by forming a hydrogen bond to Asn329, and is also a Ramachadran plot outlier in all other MCR-1 structures. Solvent-accessible loops are largely unperturbed, although loop 411–424 shifts ∼4 Å between MCR-15GRR and MCR-2CD. Based on comparison with the more distantly related phosphoethanolamine LptA (Wanty et al., 2013) and EptC (Fage et al., 2014), which have 36 and 35% sequence identity to MCR-2, respectively, loop 348–365 of MCR-2 (Fig. 2a) was suggested to be flexible and in an open conformation for substrate entry (Ma et al., 2016). However, it makes significant crystal contacts and is in similar conformations (maximum movement of 1.5 Å) in all physiologically relevant MCR structures, with low B factors in MCR-2CD (11.6 Å2). Differences in this loop compared with LptA and EptC are likely to be because the loop is longer in MCR proteins (18 residues compared with 15 and four for LptA and EptC, respectively), and may not be relevant for substrate entry. The variable amino acids of MCR-2 compared with MCR-1 are distant from both the active site and the relatively flat, proposed membrane-proximal face of the molecule (Fig. 2b). Indeed, most are located on the surface, likely facing the periplasm, with the exception of Ser459Ala on the central β-sheet. The Gln501 deletion results in a periplasmic exposed loop (Fig. 2b), rather than helical turn as in MCR-1, but is also distant from the active site. The effect of these variable amino acids on the activity is therefore likely to be minimal. However, this requires in vitro verification once both recombinant full-length enzyme is available and an assay with a suitable substrate has been developed.
MCR-2CD contains a nonphosphorylated Thr285 and clear density indicating two metal ions in the active site, modelled as zinc based on the presence of 100 µM zinc in the purification buffers and homology to MCR-1, in which zinc was identified based on scans and density functional theory calculations (Fig. 3a). As for Zn1 in MCR-1, Zn1 in MCR-2 is coordinated by Glu246, Thr285 and Asp465 (all with a coordination distance of 1.92 Å) and His466 (2.04 Å) in a tetrahedral geometry (Supplementary Table S1). Although the Zn1 coordination distances are shorter in MCR-2 compared with MCR-1 (Supplementary Table S1; Hinchliffe et al., 2017), there are no other structural differences around the Zn1 site, further underlying the importance of Zn1 to enzyme function. Similar to as in MCR-15LRM (Fig. 3b), Zn2 in MCR-2 forms a tetrahedral geometry and is coordinated by His395, His478, a tightly bound water molecule (B factor of 11.97 Å2) and Glu405 from a symmetry-related molecule. In MCR-15LRM this latter coordination is instead provided by Glu300 owing to substantially different crystal packing. This further highlights the likely lack of physiological relevance of the MCR dimer (Ma et al., 2016; Hinchliffe et al., 2017) but suggests that the second zinc site can tolerate varying coordinating ligands. The Zn2 site is unoccupied in the two nonphysiological, high zinc-content MCR-1 structures reported previously (MCR-15GOV and MCR-15K4P). MCR-15GRR is similar but contains an additional water molecule bridging Zn1 and Zn2 (Wat2; Fig. 3c). However, this water molecule has a high B factor (51.5 Å2), relatively low occupancy (0.8) and little corresponding electron density and is not in any other MCR structure, suggesting that it is nonphysiological and should not be considered in mechanistic discussions.
Superposition with the full-length MCR homologue EptA (root-mean-square deviation of 0.660 Å over 213 Cα residues; Fig. 3d, left) reveals close structural similarity between the two, as noted previously on comparison of the catalytic domains MCR-1CD and EptACD (Hinchliffe et al., 2017; Wanty et al., 2013). Indeed, despite differences in zinc occupancy (two zincs in MCR-2 and one in EptA), and the presence of DDM in EptA, the conserved active-site residues adopt similar conformations, except for small differences of the conserved His395 and His478 residues that coordinate Zn2 in MCR-2CD (Fig. 3d, right). In EptA, His478 coordinates a DDM molecule, suggesting a possible role for these residues in positioning the substrate rather than binding a second zinc ion. However, it cannot be ruled out that physiological substrates (i.e. lipid A or phosphatidylethanolamine) could replace the Glu300/Glu405–Zn2 coordination in recruiting a second zinc ion during the mechanism (Wanty et al., 2013).
The physiological relevance of the second zinc site has yet to be established, although it has now been observed in three MCR crystal structures. Our density functional theory calculations (Hinchliffe et al., 2017) suggest a two-zinc mechanism to be feasible for MCR-1, although a one-zinc mechanism was tentatively more favourable. Resolving this issue will require accurate and detailed mechanistic and computational studies of phosphoethanolamine transfer by the MCR family of enzymes, the latter of which will be greatly facilitated by the exceptionally high resolution of the current structure. The MCR-2CD structure also indicates that amino-acid mutations on the periplasmic facing surface of MCR-1 are well tolerated. This, together with the wide geographic distribution of MCR-1 and the intense current research in this area, makes it likely that further clinical MCR variants will be identified in due course. Thus, achieving full understanding of mobile colistin resistance will require consideration, including structural and biochemical characterization, of family members beyond MCR-1. The current structure represents a first step towards this goal.
Supporting information
Supplementary Table S1. DOI: https://doi.org/10.1107/S2053230X17009669/no5117sup1.pdf
Acknowledgements
We thank Diamond Light Source for access to beamline I04 (proposal No. MX12342) that contributed to the results presented here, and the staff of the Diamond Macromolecular Crystallography Village for their help.
Funding information
This work was supported by a grant from the UK Medical Research Council (MR/P007295/1) to TRW and JS.
References
Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221. Web of Science CrossRef CAS IUCr Journals Google Scholar
Anandan, A., Evans, G. L., Condic-Jurkic, K., O'Mara, M. L., John, C. M., Phillips, N. J., Jarvis, G. A., Wills, S. S., Stubbs, K. A., Moraes, I., Kahler, C. M. & Vrielink, A. (2017). Proc. Natl Acad. Sci. USA, 114, 2218–2223. CrossRef CAS PubMed Google Scholar
Berrow, N. S., Alderton, D., Sainsbury, S., Nettleship, J., Assenberg, R., Rahman, N., Stuart, D. I. & Owens, R. J. (2007). Nucleic Acids Res. 35, e45. Web of Science CrossRef PubMed Google Scholar
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M. & Rolain, J.-M. (2012). Expert Rev. Anti Infect. Ther. 10, 917–934. CrossRef CAS PubMed Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Clausell, A., Garcia-Subirats, M., Pujol, M., Busquets, M. A., Rabanal, F. & Cajal, Y. (2007). J. Phys. Chem. B, 111, 551–563. CrossRef PubMed CAS Google Scholar
Di Pilato, V., Arena, F., Tascini, C., Cannatelli, A., Henrici De Angelis, L., Fortunato, S., Giani, T., Menichetti, F. & Rossolini, G. M. (2016). Antimicrob. Agents Chemother. 60, 5612–5615. CrossRef CAS PubMed Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Evans, P. R. & Murshudov, G. N. (2013). Acta Cryst. D69, 1204–1214. Web of Science CrossRef CAS IUCr Journals Google Scholar
Fage, C. D., Brown, D. B., Boll, J. M., Keatinge-Clay, A. T. & Trent, M. S. (2014). Acta Cryst. D70, 2730–2739. CrossRef IUCr Journals Google Scholar
Falgenhauer, L., Waezsada, S. E., Yao, Y., Imirzalioglu, C., Käsbohrer, A., Roesler, U., Michael, G. B., Schwarz, S., Werner, G., Kreienbrock, L. & Chakraborty, T. (2016). Lancet Infect. Dis. 16, 282–283. CrossRef CAS PubMed Google Scholar
Fernandes, M. R., McCulloch, J. A., Vianello, M. A., Moura, Q., Perez-Chaparro, P. J., Esposito, F., Sartori, L., Dropa, M., Matte, M. H., Lira, D. P., Mamizuka, E. M. & Lincopan, N. (2016). Antimicrob. Agents Chemother. 60, 6415–6417. CrossRef CAS PubMed Google Scholar
Haenni, M., Poirel, L., Kieffer, N., Chatre, P., Saras, E., Metayer, V., Dumoulin, R., Nordmann, P. & Madec, J.-Y. (2016). Lancet Infect. Dis. 16, 281–282. CrossRef CAS PubMed Google Scholar
Hinchliffe, P. et al. (2017). Sci. Rep. 7, 39392. CrossRef PubMed Google Scholar
Hu, M., Guo, J., Cheng, Q., Yang, Z., Chan, E. W. C., Chen, S. & Hao, Q. (2016). Sci. Rep. 6, 38793. CrossRef PubMed Google Scholar
Karaiskos, I., Souli, M., Galani, I. & Giamarellou, H. (2017). Expert Opin. Drug Metab. Toxicol. 13, 59–71. CrossRef CAS PubMed Google Scholar
Krissinel, E. & Henrick, K. (2004). Acta Cryst. D60, 2256–2268. Web of Science CrossRef CAS IUCr Journals Google Scholar
Li, A., Yang, Y., Miao, M., Chavda, K. D., Mediavilla, J. R., Xie, X., Feng, P., Tang, Y.-W., Kreiswirth, B. N., Chen, L. & Du, H. (2016). Antimicrob. Agents Chemother. 60, 4351–4354. CrossRef CAS PubMed Google Scholar
Li, R., Xie, M., Zhang, J., Yang, Z., Liu, L., Liu, X., Zheng, Z., Chan, E. W.-C. & Chen, S. (2016). J. Antimicrob Chemother. 72, 393–401. CrossRef PubMed Google Scholar
Liu, Y.-Y. et al. (2016). Lancet Infect. Dis. 16, 161–168. CrossRef PubMed Google Scholar
Lo, W.-U., Chow, K.-H., Law, P. Y., Ng, K.-Y., Cheung, Y.-Y., Lai, E. L. & Ho, P.-L. (2014). J. Med. Microbiol. 63, 835–840. CrossRef CAS PubMed Google Scholar
Ma, G., Zhu, Y., Yu, Z., Ahmad, A. & Zhang, H. (2016). Sci. Rep. 6, 39540. CrossRef PubMed Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Mediavilla, J. R., Patrawalla, A., Chen, L., Chavda, K. D., Mathema, B., Vinnard, C., Dever, L. L. & Kreiswirth, B. N. (2016). MBio, 7, e01191-16. CrossRef PubMed Google Scholar
Stojanoski, V., Sankaran, B., Prasad, B. V., Poirel, L., Nordmann, P. & Palzkill, T. (2016). BMC Biol. 14, 81. Google Scholar
Wanty, C., Anandan, A., Piek, S., Walshe, J., Ganguly, J., Carlson, R. W., Stubbs, K. A., Kahler, C. M. & Vrielink, A. (2013). J. Mol. Biol. 425, 3389–3402. Web of Science CrossRef CAS PubMed Google Scholar
Waterman, D. G., Winter, G., Gildea, R. J., Parkhurst, J. M., Brewster, A. S., Sauter, N. K. & Evans, G. (2016). Acta Cryst. D72, 558–575. Web of Science CrossRef IUCr Journals Google Scholar
Wiese, A., Gutsmann, T. & Seydel, U. (2003). J. Endotoxin Res. 9, 67–84. PubMed CAS Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Xavier, B. B., Lammens, C., Ruhal, R., Kumar-Singh, S., Butaye, P., Goossens, H. & Malhotra-Kumar, S. (2016). Euro Surveill. 21, https://doi.org/10.2807/1560-7917.ES.2016.21.27.30280. CrossRef Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.